Georgina V. Long, MD, MSc, discussed the long-term follow-up data for the combination of adjuvant dabrafenib and trametinib in stage III BRAF-mutated melanoma.
2025
Truong Factors Age and High-Grade Toxicity Risk Into IO Selection in Melanoma
EVENT REGION Illinois, Minnesota, Nebraska, Wisconsin
Tilsotolimod Provides No Added Benefit in Advanced Melanoma
The combination of tilsotolimod and ipilimumab does not improve response rates or survival outcomes over ipilimumab alone in patients with advanced melanoma, according to phase 3 trial results published in the Journal of Clinical Oncology.
Amaria Highlights Phase 1 Trial of OBX-115 in Melanoma
According to Amaria, early data from the phase 1 study, including findings presented at the 2024 American Society of Clinical Oncology Annual Meeting were encouraging, as OBX-115 was shown to be well-tolerated and did not lead to any severe adverse events.